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Abstract
Background: Recent preclinical adoptive immunotherapy studies in murine models prompt to employ “proper”
rather than “as many as possible” antigen-specific T cells to gain better therapeutic results. Ideally, “proper” T cells
are poorly differentiated in vitro, but retain the capacity to fully differentiate into effector cells in vivo, where they
can undergo long-term survival and strong proliferation. Such requirements can be achieved by modifying culture
conditions, namely using less “differentiating” cytokines than IL-2.
Methods: To evaluate this issue in human T cell cultures, we exploited a well characterized and clinical-grade
protocol finalized at generating EBV-specific CTL for adoptive immunotherapy. In particular, we studied the impact
of IL-7, IL-15 and IL-21 compared to IL-2 on different aspects of T cell functionality, namely growth kinetics,
differentiation/activation marker expression, cytokine production, and short-term and long-term cytotoxicity.
Results: Results disclosed that the culture modifications we introduced in the standard protocol did not improve
activity nor induce substantial changes in differentiation marker expression of EBV-specific CTL.
Conclusions: Our data indicated that the addition of g-chain cytokines other than IL-2 for the generation of EBV-
specific T cell cultures did not produce the improvements expected on the basis of recent published literature. This
fact was likely due to the intrinsic differences between murine and human models and highlights the need to
design ad hoc protocols rather than simply modify the cytokines added in culture.
Background
Infusion of antigen-specific T cells proved to be safe and
effective against both virus infections (e.g., CMV [1])
and cancer, in particular melanoma and EBV-driven
malignancies [2]. The vast majority of current protocols
rely on the infusion of a high number of effector cells
that require long-term in vitro cultures, in particular
when dealing with Tumor Infiltrating Lymphocytes
(TIL) or clonal cultures. Consequently, this aspect
implies labor-intensive and cost-ineffective procedures
and, furthermore, has a potential negative impact on the
characteristics of cells infused. Indeed, as advanced by
Gattinoni and colleagues [3,4], long-term T cell cultures
move toward a differentiated phenotype characterized
by a high cytotoxic potential, but also a poor
recirculation and in vivo expansion capability. These fea-
tures are highlighted by a well-defined “marker expres-
sion signature”,n a m e l yC D 2 7
low/neg,C D 2 8
low/neg,
CD62L
low/neg, CCR7
low/neg, and CD57
high. Thus, the new
trend in adoptive cell therapy (ACT) focuses on the
infusion of a more limited number of cells, but with the
“proper” phenotype and functional characteristics, which
can promote prolonged in vivo persistence and expan-
sion, and induction of immunological memory to pro-
vide protection against possible relapses. The
potentiality to expand and persist in the host also relies
on the possibility for the infused cells to find an “immu-
nological space” to colonize. This is “naturally” accom-
plished in Post Transplant Lymphoproliferative Disease
(PTLD) after Haemopoietic Stem Cell Transplantation
(HSCT), in which patients are immunocompromised
due to the immunosuppressive regimens; in patients
with other tumors, it has been achieved by chemother-
apy and irradiation [5] or by immunodepleting (anti-
CD45) antibodies [6]. In these conditions, infused T
cells have a favourable environment with fewer
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any medium, provided the original work is properly cited.competitors for and elevated availability of homeostatic
cytokines (IL-7 and IL-15), and possibly less numerous
T regulatory (Treg) populations.
Although much attention has been paid to shorten the
generation protocols in the clinical settings, a stringent
correlation between phenotype (and so differentiation)
and outcome has been shown mainly in mouse models
thus far [4,7,8], with few notable exceptions [9]. In this
context, several reports have described the impact of dif-
ferent g-chain cytokines on the differentiation status and
functional properties of T-cell cultures in vitro and,
more importantly, in vivo. Overall, they suggested that
certain g-chain cytokines, in particular IL-15 and IL-21,
are superior to the commonly used IL-2 in maintaining
a less differentiated phenotype of cultured T cells, thus
possibly resulting in a better therapeutic activity. In this
regard, the eradication of large established melanomas
(approximately 50 mm
2 tumor area) was achieved by
the infusion of as little as 5 × 10
5 IL-21 cultured T cells
[7].
To explore this critical issue in human T cell cultures,
we took advantage of a well established and clinical-
graded protocol aimed at generating EBV-specific CTL
for ACT. We slightly modified the protocol by adding
to the cultures IL-7, IL-15 or IL-21 instead of IL-2.
Moreover, we separated and maintained in parallel cul-
tures CD4
+ and CD8
+ T cells to better discriminate the
impact of the different cytokines on the two subsets.
We therefore compared the proliferative potential, phe-
notype, cytokine production, and cytotoxic activity of
effector cells obtained in different culture conditions.
On the whole, addition of different cytokines did not
produce any clear improvement or substantial differ-
ences between T cell lines. Therefore, to obtain more
active T cells for therapy, we infer that several other
conditions need to be optimized other than the use of
different cytokines, namely ad hoc protocols able to
appropriately balance the effector cell expansion and the
timing of culture.
Methods
Lymphoblastoid cell lines (LCL)
EBV-transformed lymphoblastoid cells were generated
from peripheral blood mononuclear cells of HLA-typed
healthy donors using culture supernatant from the EBV-
producing marmoset cell line B95.8 (American Type
Culture Collection). Signed informed consent was
obtained from the donors and the research protocol was
approved by the institutional ethical review board of the
Istituto Oncologico Veneto, in accordance with the ethi-
cal standards of Helsinki Declaration.
Cyclosporin A (CsA, Sandoz Pharmaceuticals AG;
Cham, Switzerland) was initially added to the cultures
to inhibit T cell growth (final concentration, 700 ng/ml).
LCL were maintained in RPMI 1640 (Euroclone, Pero,
Milan, Italy) supplemented with 10% heat-inactivated
type AB Human Serum (HS, Lonza BioWhittaker; Basel,
Switzerland), 1 mM Na Pyruvate, 10 mM Hepes Buffer,
2 mM Ultraglutamine (all from Lonza BioWhittaker),
1% Antibiotic/antimycotic (Gibco, Invitrogen Corpora-
tion), hereafter referred to as HS complete medium.
Generation of EBV-specific CD4
+ and CD8
+ T-cell lines
EBV-specific T cells were established as previously
described [10], with modifications. Briefly, PBMC were
co-cultivated with irradiated (40 Gy) autologous LCL at
a ratio of 40:1 in 24-well plates (Corning Incorporated;
Corning, NY) in HS complete medium. PBMC were
seeded at a concentration of 2 × 10
6 cells/ml and main-
tained at 37°C in a 6.5% CO2 humidified atmosphere.
On day 10 and weekly thereafter, CTL were re-stimu-
lated with irradiated LCL at a 4:1 ratio. Recombinant
IL-2 (35 I.U./ml, Proleukin, Chiron Corporation; Emery-
ville, CA) or IL-7 (10 ng/ml; Peprotech; Rocky Hill, NJ)
or IL-15 (10 ng/ml; Peprotech) or IL-21 (10 ng/ml;
eBioscience; San Diego, CA) were added on day 14 and
replenished every 2 days. On day 14, before cytokine
addition, CD4
+ T cells were immunomagnetically sorted
using the CD4
+ T cell Isolation Kit II (Miltenyi Biotec;
Bergisch Gladbach, Germany), and both CD8
+ and CD4
+ T cells were cultured in parallel. At each subsequent
re-stimulation with LCL, CD4
+ T cells were adjusted to
1.5 × 10
6 cells/ml and CD8
+ T cells to 2 × 10
6 cells/ml.
Cytotoxicity assays
Cytotoxic activity of CD4
+ and CD8
+ T cells was deter-
mined in a standard 4-h
51Cr release assay, as previously
reported [11]. Autologous LCL were used as target cells,
while K562 cell line served as indicator of NK-like activ-
ity. All tests were carried out with an excess of
unmarked ("cold”) K562 (5:1 ratio between “cold” and
“hot” target). Where indicated, CD4
+ T cells were pre-
treated for 2 h at 37°C with either 20 μM brefeldin A
(BFA, Sigma-Aldrich; St. Louis, MO) or 100 nM conca-
namycin A (CMA, Sigma-Aldrich) and assayed in the
presence of the drugs. To assess calcium-dependence of
cytolytic activity, 4 mM EGTA (Sigma-Aldrich) was
added to the assay. For antibody blocking experiments,
T cells were pre-incubated with 10 μg/ml of anti-FasLi-
gand mAb (clone NOK-1; BioLegend; San Diego, CA).
Flow cytometry
Surface markers were determined by staining with
FITC- or PE-conjugated antibodies and the respective
isotypes. CTL lines were stained with antibodies to
CD3, CD16, CD56 (BD-Pharmingen; San Diego, CA),
CD4 and CD8 (BD Biosciences; San Diego, CA), CCR7
(eBioscience), CD27, CD28, CD57, CD62L and CD127
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5)w e r ew a s h e dw i t h
phosphate-buffered saline (PBS; Sigma-Aldrich) and re-
suspended in 50 μl of staining solution (PBS, 3% FBS
and 0,1% NaN3) containing an optimal concentration of
antibody. After a 20-minute incubation in ice, cells were
washed again and analyzed using a FacsCalibur (BD)
flow cytometer. Flow cytometry data were analyzed with
FlowJo software (Tree Star, Inc.; Ashland, OR).
ELISA test
Cytokine ELISA tests were performed using Human
TNFa Screening Set and Human IFNg Screening Set
(Thermo Scientific, Rockford, IL), according to the man-
ufacturer’s instructions. Briefly, 2 × 10
5 effector cells and
2×1 0
5 autologous LCL were seeded in 96-well round-
bottom plates. Positive controls were represented by
effector T cells incubated with PMA-ionomycin (40 ng/
ml and 4 μg/ml, respectively; Sigma-Aldrich). Baseline
cytokine production was determined in supernatants
from unstimulated T cells, or LCL only. Cytokine secre-
tion was measured after 5h-incubation.
Outgrowth assay
Outgrowth assay was carried out as previously described
[12]. Briefly, target LCL were seeded as replicates in U-
bottom 96-well plates at doubling dilution, starting from
10
4 cells/well to 78 cells/well. T cells were added to half
of the replicates at 10
4 cells/well in HS complete med-
ium without IL-2. Plates were then incubated at 37°C in
6.5% CO2 and re-feeded weekly by replacing half of the
medium. LCL outgrowth was scored after 4 weeks by
visual examination with an inverted microscope. Results
are expressed as the minimum number of LCL required
for successful outgrowth in 50% of replicate wells.
Results
Analysis of in vitro growth kinetics
To dissect the impact of different g-chain cytokines on
human T cell in vitro expansion, we took advantage of a
well defined protocol aimed at generating EBV-specific
T cells cultures [10,13]. First, we evaluated the prolifera-
tive potential of CTL lines cultured with IL-15, IL-7 or
IL-21 in comparison to IL-2. Briefly, we seeded PBMC
from healthy donors with autologous LCL without cyto-
kine addition for the selection phase. Two weeks later,
the expansion phase was started by supplying different
cytokines to purified CD8
+ and CD4
+ T cells, to assess
their proliferative response. As expected, we found that
both CD8
+ and CD4
+ T cells grew vigorously when cul-
tured with IL-2, although with differential magnitudes.
In particular, CD4
+ T cells grew for a longer time (more
than 14 weeks) in comparison to CD8
+ T cells, which
disclosed an initial phase of logarithmic growth followed
by a progressive reduction of their active proliferation
after 3 to 7 re-stimulations (Figure 1 and data not
shown). IL-15 produced a similar trend in CD4
+ and
CD8
+ T cell growth and proved to be superior to other
tested cytokines in inducing the expansion of both sub-
populations, while IL-7 supported the expansion of CD4
+
T cells only, albeit at different degrees of magnitude
for different donors. In deep contrast, IL-21 alone
allowed survival but did not sustain the expansion of
either subsets of T cells, in line with previously reported
data [14-16].
Assessment of phenotype
The use of different cytokines in culture could impact
on differentiation, trafficking and functional properties
of T cells, characteristics that have a counterpart on
specific surface marker expression [3]. We therefore
analyzed the expression of CD27, CD28, CD57, CD62L,
IL7Ra, and CCR7 at different time points during cul-
ture. We performed flow cytometry analysis at day 0
just before seeding, at day 14 before immunomagnetic
separation and cytokine addition, and after 1 month of
culture. At 2 months, phenotype of CD4
+ T cells only
could be evaluated, since CD8
+ T lymphocytes did not
proliferate so long. The phenotype of IL-21 T cells
could not be determined due to the low number of lym-
phocytes obtained in these cultures. As shown in Figure
2, overall we found more pronounced differences in the
phenotypic profile of CD8
+ and CD4
+ T cells prior to
the addition of the various cytokines than after their
supplement to cultures. Indeed, immediately after ex
vivo collection, nearly all CD4
+ T cells expressed CD27,
CD28, CD62L, IL7Ra, in comparison to only about 50%
of CD8
+ T cells. Conversely, CD8
+ T cells tended to
acquire CD27 and CD28 expression in culture, differ-
ently from what observed by Vanhoutte et al. [17], while
IL7Ra and CD62L were poorly represented in this sub-
set respect to the CD4
+ T cell counterpart. These latter
cells, on the contrary, partly lost the CD27 expression
during culture. The expression of CCR7, which
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Figure 1 Growth kinetics of CD4
+ and CD8
+ T cell lines.T h e
extrapolated mean total cell counts of CD4
+ (left) and CD8
+ (right)
T cell lines cultured with IL-2, IL-7, IL-15 and IL-21 before each re-
stimulation with LCL is represented. Figure shows mean values from
at least two independent experiments.
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Figure 2 Expression of maturation/differentiation markers. Figure shows marker expression by CD4
+ and CD8
+ T cells at day 0, 14 (before
separation and cytokine supply), 1 month and, for CD4
+ T cells only, 2 months. Figure shows mean +/- SD of 3 replicate cultures from 2 donors.
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Page 4 of 8appeared initially quite variable between CD4
+ and
CD8
+ T cells, was lost by all T cell lines from the third
week of culture and thereafter (data not shown); on the
other hand, CD44 was expressed at high intensity in
nearly all T cells for the entire period of culture (data
not shown). CD57 expression was quite different
between CD4
+ and CD8
+ T cells (4.35 +/- 3.44% versus
22.99 +/- 5.15% immediately after ex vivo collection,
respectively); in fact, it was rapidly up-regulated and
then lost by CD4
+ T cells, while retained by CD8
+
T cells (data not shown). Finally, after 1 month of cul-
ture the phenotypic profile tended to stabilize and did
n o tf u r t h e rm o d i f ys u b s t a n t i a l l ya tl e a s tf o rt h eC D 4
+
T cell subset, the only one that could be tested.
Evaluation of cytokine production
Next, we investigated the production of cytokines by
cultures in response to different stimuli, such as autolo-
gous LCL and PMA-ionomycin, to verify whether the
conditions tested have an impact on cytokine produc-
tion. In particular, we studied the production of Th1
cytokines, namely IFNg and TNFa, which play an
important role in anti-tumor immunity [18,19]. We
found that IL-2, IL-7, and IL-15 CD8
+ Tc e l lc u l t u r e s
produced comparable amounts of IFNg and TNFa in
response to both stimuli (Figure 3). Moreover, while IL-
2, IL-7, and IL-15 CD4
+ T cells did not display relevant
differences in the amount of TNFa secreted, IL-2 and
IL-15 CD4
+ T cells produced a higher amount of IFNg
in response to LCL stimulation in comparison to IL-7
cultures, but comparable levels in response to PMA-
ionomycin (Figure 3). Cytokine production by IL-21 T
cells could not be assessed due to the low number of
lymphocytes obtained in cultures.
Analysis of in vitro functional activity
In vitro functional activity was assessed both in short-
term and long-term assays. Standard cytotoxicity tests
were performed with T cell lines at 21 days of culture.
At this time point (third restimulation, see Figure 1), we
could test all the cell lines obtained but IL-21 CD4
+ T
cells. Although NK cell presence was negligible (< 1%),
nevertheless all tests were carried out in the presence or
absence of an excess of “cold” K562 to eliminate any
possible influence of NK-like activity. As shown in
Figure 4a, the addition of different cytokines did not
modify the lytic activity of either CD8
+ or CD4
+ T cells.
Notably, in contrast with recently published data [7],
IL-21-cultured CD8
+ T cells showed a strong lytic activ-
ity similar to that of cognate IL-2 cultures. To assess the
mechanisms involved in lytic activity we focused on
CD4
+ T cells, as no clear preferential use of granule
exocytosis or apoptosis induction is described for this
subset. By using compounds that selectively inhibit per-
forin-based or Fas/FasL-based pathway, we found that
all CD4
+ T cells obtained, irrespectively of culture con-
ditions, killed their targets through the cytotoxic granule
content release (Figure 4b). These findings are in line
with our previous observations [13] and the vast major-
ity of data related to EBV-specific cultures [20]. Once
again, cytokines used in cultures did not modify func-
tional activity.
Although commonly used to evaluate functionality of
effector T cells, the cytotoxic activity does not always
correlate with in vivo efficacy, as recently demon-
strated not only in mouse models [4] but also in clini-
cal trials [21]. After adoptive transfer, a clue
characteristic is the capacity of effector cells to per-
form sequential killings before exhaustion. As this
issue can not be adequately addressed in a short-term
test, we performed outgrowth assays that evaluate the
ability of a fixed input of T cells to inhibit long-term
growth of different numbers of target cells, without the
addition of cytokines. This experimental design closely
resembles in vivo adoptive transfer protocols, which
are based on a single infusion of effector T cells with-
out exogenous cytokine supply [13,22]. In both cases,
T cells do not likely survive longer than a few days,
when they can display their killing potential. Thus, the
extent of target elimination could be predictive of the
outcome: even few surviving tumor cells can ultimately
lead to a successful microculture outgrowth or to the
death of the engrafted animals. Due to the low number
CD4+ CD8+
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Figure 3 Th1 cytokine production. Figure shows TNFa and IFNg
production by CD4+ (left panel) and CD8+ (right panel) T cells in
response to stimulation with autologous LCL or PMA-ionomycin, or
unstimulated (us), as assessed by ELISA test. Figure shows mean ±
SD of 3 replicate cultures from 2 donors.
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Page 5 of 8of cells required (as few as 0.32 × 10
6 cells for each
test), in this case we could test every cell line obtained.
In line with our previous results (data not shown), IL-
2-cultured CD8
+ T cells disclosed a superior ability to
inhibit long-term growth of target cells in comparison
to their CD4
+ T cell counterpart; a similar trend was
observed for CD8
+ T lymphocytes cultured in IL-7 or
IL-15. Instead, the reverse was true for CD8
+ T cells
supplied with IL-21. Finally, striking was the finding
that IL-15 CD4
+ T cells, despite a vigorous in vitro
cytotoxic activity in short-term assay, did not exert any
inhibitory potential (Figure 5).
Discussion
Recent advances in immunotherapeutic approaches have
highlighted the importance of infusing antigen-specific
T cells that have ideally a poorly differentiated pheno-
type and are characterized by a strong proliferative
potential upon in vivo transfer. These conditions have
been partially met by acting on recipient patients with
lymphodepleting strategies or by proposing the shorten-
ing of T cell in vitro expansion protocols with the use
of “less differentiating” cytokines. With regard to this
latter issue, we exploited a protocol successfully used in
immunotherapeutic approaches for EBV-related
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Figure 4 Lytic activity of EBV-specific CD8
+ and CD4
+ Tc e l l s . A) Cytotoxic activity was tested by standard 4 h
51Cr-release assay in the
presence of “cold” K562 at a 5:1 ratio of “cold": “hot” target. B) Lytic mechanisms involved in cytotoxicity. CD4
+ T cell line cytotoxicity was
evaluated in the presence of CMA and EGTA that block perforin-based pathway, and BFA and anti-FasL mAb that interfere with Fas/FasL-based
pathway. Figure shows mean values from 3 independent experiments carried out for each donor cell line.
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cytokines on phenotype and functionality of cultured T
cells, as suggested by recent studies [4,7,8]. We analyzed
purified CD8+ and CD4+ T cells to avoid potential
influence of one population on the other one; indeed,
despite a trend toward a “natural” expansion of CD8+T
cells, the percentage of CD4+T cells in cultures turns
out to be quite various among different donors and dif-
ferent preparations from the same donor. Our choice
furthermore took into account the increasing attention
paid on the CD4
+T cells as actual effector cells in
immunotherapeutic approaches [23,24].
Intriguingly, the results presented herein are pro-
foundly different from those of recently published stu-
dies. Previous reports, in fact, mainly rely on murine T
cells derived from mice expressing transgenic TCR spe-
cific for the antigen of interest. All T cells have there-
fore the desired specificity and hence they only need to
be activated in vitro, bypassing a potentially long selec-
tion phase. Conversely, this phase was absolutely
required by our protocol, and covered the first 14 days
of culture. Moreover, our protocol envisages the addi-
tion of cytokine only after this phase. During this gap,
EBV-specific T cells that are present in PBMC of sero-
positive donors respond to the viral antigens presented
by LCL, very likely producing IL-2 that in turn can
influence the culture. In this regard, IL-21 has been
reported to be capable of reverting the IL-2-induced dif-
ferentiation [7], but no information is available for IL-7
and IL-15. In addition, it must be noted that in vitro
expansion selectively involved EBV-specific precursors
belonging to the memory compartment and therefore
the obtainment of less differentiated cells is expected to
be difficult. The long and likely confounding selection
phase could be bypassed by performing faster (e.g., over-
night) peptide mix stimulation followed by immunomag-
netic isolation of cytokine-producing T cells, as recently
proposed [25], or by introducing the wanted antigen
specificity through CAR- or transgenic TCR-coding vec-
tor transduction [26,27]. In these cases, the alternatively
chosen cytokines could be added in a less precondi-
tioned milieu, thus driving a less pronounced differen-
tiation of responding T lymphocytes, or, in the case of
CAR or TCR transfer, of the whole population of trans-
duced peripheral T cells.
Overall, although the use of g-chain cytokines other
than IL-2 did not produce any substantial in vitro
improvement, a realistic and clear-cut description of the
activity of a determined T cell population should be
derived by in vivo studies. In this regard, however, we
c o u l dn o tp r o d u c ed e f i n i t i v er e s u l t ss i n c ew eo n l yh a d
the possibility to test those cultures that reach a suffi-
cient number for infusion. Moreover, the PTLD-SCID
mouse model suffers from different intrinsic biases that
might have frustrated the purpose of our study. In fact,
we have evidence that human T cells survive no longer
than 24 hr after in vivo transfer [13], even when this fol-
lows irradiation or cyclophosphamide treatment of reci-
pient mice. Moreover, this poor survival was verified not
only for EBV-specific T cells, but also for less differen-
tiated, CAR-transduced antigen-specific T cells (data not
shown). In addition, due to the intrinsic differences
between mouse and human adhesion molecules and
receptors, it is hard to evaluate the lymph node homing
and recirculation capacity that have a fundamental role
in the more physiological model described by Gattinoni
et al. [4], which envisages the transfer of mouse T cells
into a syngeneic murine microenvironment. In such
experimental context, moreover, the concomitant vacci-
nation strategies make the lymph node homing proper-
ties even more relevant, as they dramatically contribute
to the improvement of the final outcome [4]. Thus, it is
left to be verified in a human context the impact of dif-
ferent lymphoid homing marker expression on the out-
come of adoptive transfer strategies.
Conclusions
As a whole, our results indicate the need to design ad
hoc protocols to appreciate the impact of g-chain cyto-
kines other than IL-2 on the functionality of CTL for
adoptive cell therapy.
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